|
HY-15579A-5mg
|
MedChemexpress LLC
|
MMAF (hydrochloride) [CAS 1415246-68-2]
|
|
Cancer-programmed cell death
|
|
|
HY-15579A-50mg
|
MedChemexpress LLC
|
MMAF (hydrochloride) [CAS 1415246-68-2]
|
|
Cancer-programmed cell death
|
|
|
HY-15579B-10mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-15579B-100mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-15579B-5mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-15579B-50mg
|
MedChemexpress LLC
|
MMAF (sodium) [CAS 1799706-65-2]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-15579-10mg
|
MedChemexpress LLC
|
MMAF [CAS 745017-94-1]
|
|
Cancer-programmed cell death
|
|
|
HY-15579-100mg
|
MedChemexpress LLC
|
MMAF [CAS 745017-94-1]
|
|
Cancer-programmed cell death
|
|
|
HY-15579-5mg
|
MedChemexpress LLC
|
MMAF [CAS 745017-94-1]
|
|
Cancer-programmed cell death
|
|
|
HY-15579-50mg
|
MedChemexpress LLC
|
MMAF [CAS 745017-94-1]
|
|
Cancer-programmed cell death
|
|
|
HY-79253-100mg
|
MedChemexpress LLC
|
MMAF intermediate 1 [CAS 161485-82-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-79253-25mg
|
MedChemexpress LLC
|
MMAF intermediate 1 [CAS 161485-82-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-79253-50mg
|
MedChemexpress LLC
|
MMAF intermediate 1 [CAS 161485-82-1]
|
|
Neuroscience-Neuromodulation
|
|
|
HY-79254-100mg
|
MedChemexpress LLC
|
MMAF intermediate 2 [CAS 864238-20-0]
|
|
|
|
|
HY-79254-25mg
|
MedChemexpress LLC
|
MMAF intermediate 2 [CAS 864238-20-0]
|
|
|
|
|
HY-79254-50mg
|
MedChemexpress LLC
|
MMAF intermediate 2 [CAS 864238-20-0]
|
|
|
|
|
HY-P73806-20ug
|
MedChemexpress LLC
|
Moesin, Human (His)
|
|
|
|
